Clinical Study on Efficacy and Safety of Hetrombopag in the Preoperative Patients of Thrombocytopenia
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
This is an investigator-initiated, single-arm, prospective clinical study to evaluate the efficacy and safety of heptapopal in the treatment of thrombocytopenia prior to elective surgery
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Age ≥18 years old; diagnosis of immune thrombocytopenia.
• Platelets ≤75×10\^9/L before scheduled elective surgery.
Locations
Other Locations
China
Chengdu Third People's Hospital
RECRUITING
Chengdu
Contact Information
Primary
Ying Li, PhD
79468064@qq.com
+86 028 61318717
Backup
Zuofeng Liu, Master
641206088@qq.com
+86 028 61318717
Time Frame
Start Date: 2024-06-01
Estimated Completion Date: 2025-03-31
Participants
Target number of participants: 55
Treatments
Experimental: Experimental: Hetrombopag arm
Takes Hetrombopag 7.5 mg/day at bedtime for at most 14 days.
Related Therapeutic Areas
Sponsors
Leads: The Third People's Hospital of Chengdu
Collaborators: Affiliated Hospital of North Sichuan Medical College